Skip to content
OpenCapital
Get started

Surgery Partners, Inc. SGRY Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net

Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net at other companies

Tenet Healthcare logo
Tenet HealthcareTHC
——

Other financials

Income statement

See full
Revenue$810.9M+4.5%
Operating income$65.8M+6.3%
Net income-$35.9M+4.8%
EPS (diluted)-$0.28+6.7%

Balance sheet

See full
Cash & equivalents$182.3M-20.5%
Total debt$5.1B+4.6%
Total equity$1.7B-3.0%
Total assets$8.0B+1.2%

Cash flow

See full
Operating cash flow$11.7M+95.0%
CapEx$16.0M-29.5%
Free cash flow-$4.3M+74.3%

Valuation

See full
Market cap$1.99B-49.1%

Profitability

See full
Gross margin23.1%—
Operating margin11.8%+1.2pp
Net margin-2.3%-0.9pp
FCF margin6.2%+0.8pp

Returns & leverage

See full
Return on equity-4.4%-1.6pp
Debt / equity3×+0.2×
Current ratio1.9×0.0×

Where this comes from

Reported directly by Surgery Partners, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet.

The official record: Surgery Partners, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Surgery Partners, Inc.'s debt instrument, unamortized discount (premium) and debt issuance costs, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Surgery Partners, Inc.'s debt instrument, unamortized discount (premium) and debt issuance costs, net?
Surgery Partners, Inc. (SGRY) reported debt instrument, unamortized discount (premium) and debt issuance costs, net of $31.2M in Q1 2026.
How has Surgery Partners, Inc.'s debt instrument, unamortized discount (premium) and debt issuance costs, net changed year-over-year?
Surgery Partners, Inc.'s debt instrument, unamortized discount (premium) and debt issuance costs, net decreased by 2.2% year-over-year, from $31.9M to $31.2M.
What is the long-term trend for Surgery Partners, Inc.'s debt instrument, unamortized discount (premium) and debt issuance costs, net?
Over 5 years (2020 to 2025), Surgery Partners, Inc.'s debt instrument, unamortized discount (premium) and debt issuance costs, net has grown at a 14.4% compound annual growth rate (CAGR), from $16.3M to $32M.